Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance

Exclusion Criteria

• •A diagnosis of Type 2 diabetes mellitus at any time
• •Pregnant, lactating or intending to become pregnant during the study or within 3 months after the study dose is administered
• •Uncontrolled intercurrent illness or any psychiatric illness
• •Participants actively involved in a weight loss or dietary program within the last 6 months
• •History of surgical procedures for weight loss
• •History of eating disorder
• •Uncontrolled hypertension (systolic \>/=140 millimeter of mercury \[mmHg\] or diastolic blood pressure \>/=90 mmHg) either on or off therapy at screening or Day -2
• •Fasting triglycerides \>500 mg/dL (5.64 millimoles per liter \[mmol/L\]) or low density lipoprotein (LDL) \>160 mg/dL (4.14 mmol/L) at screening
• •Any serious medical condition or abnormality in clinical laboratory tests